U.S., Dec. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07303660) titled 'A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients' on Dec. 05.
Brief Summary: This is a clinical study aiming to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory Acute Myeloid Leukemia patients.
Study Start Date: Jan. 10, 2026
Study Type: INTERVENTIONAL
Condition:
Acute Myeloid Leukemia
Intervention:
DRUG: ZE50-0134
Oral capsules BID
DRUG: Azacitidine Days 1-7
75 mg/m2 daily, days 1-7
DRUG: ZE 50-0134
Oral capsules QD
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Lomond Therapeutics Holdings, Inc.
Published by HT Di...